Produktname:2,2-Difluoroethylamine

IUPAC Name:2,2-difluoroethan-1-amine

CAS:430-67-1
Molekulare Formel:C2H5F2N
Reinheit:95%+
Katalognummer:CM117573
Molekulargewicht:81.07

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM117573-100g 3-4 Weeks ƴǟƈ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:430-67-1
Molekulare Formel:C2H5F2N
Schmelzpunkt:-
SMILES-Code:NCC(F)F
Dichte:
Katalognummer:CM117573
Molekulargewicht:81.07
Siedepunkt:
Mdl-Nr.:MFCD00798137
Lagerung:

Category Infos

Fluorinated Compounds
Fluorine is the most electronegative element in the periodic table, and the fluorine atom has a small atomic radius, so fluorine-containing organic compounds have many wonderful properties. For example, the introduction of fluorine atoms or fluorine-containing groups into drug molecules can improve the permeability to cell membranes, metabolic stability and bioavailability; in addition, the introduction of fluorine atoms will improve the lipid solubility of the compound and promote its absorption in the body. The speed of delivery changes the physiological effect. In the field of medicinal chemistry, the introduction of fluorine atoms into organic molecules is an important direction for the development of new anticancer drugs, antitumor drugs, antiviral agents, anti-inflammatory drugs, and central nervous system drugs.

Column Infos

Nitrogen Compounds
Nitrogen compounds can be classified as mineral or organic. Mineral compounds are essentially formed by the ammonium ion (NH4+), which is generated when ammonium salts are dissolved in water. Organic compounds, in contrast, are carbon and hydrogen compounds that contain a nitrogen atom. All organic nitrogen-containing compounds can be considered as derivatives of ammonia in which one or more hydrogen atoms are substituted by hydrocarbon radicals.
Fluorinated compounds
Fluorinated compounds refers to organic or inorganic compounds containing fluorine.
Bexicaserin
Longboard announced positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). The analysis showed that bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures across the DEE study population. Longboard will rapidly advance bexicaserin's global Phase 3 trial.

Related Products